Our Mission is to develop the broadest range of clinical therapies with our breakthrough discoveries to benefit as many patients as possible suffering from cancerous metastatic bone and soft tissue lesions.

“Research never ceases at Zetagen because cancer never rests…”

We are appreciative to have the financial support of our investors and the National Institute of Health (NIH) through their variety of Small Business Innovation Research (SIBR) programs to support our research. Zetagen’s preclinical research is funded through a series of phase I and II grants from the National Cancer Institute (NCI) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH. 

ZetaMet™ (Zeta-BC-003) was recently awarded a Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic bone cancer. Currently, ZetaMet™ (Zeta-BC-003) has been approved by Health Canada for a clinical trial which is currently enrolling for the treatment of metastatic breast cancer lesions to the spine.


We are developing an AI-inspired machine learning technology that will leverage Zetagen’s intellectual property (Zeta-Platform) and substantial study data to predictably identify patterns in a wide variety of tumor types that can be treated using novel therapeutic innovations. 

  1. Machine learning will be used to identify patterns based on tumor genetics and patient demographic information that will be used to develop a diagnostic tool that identifies tumors that can be successfully treated using Zetagen’s novel pharmaceutical intervention.  
  2. Pre-clinical data that led to the breakthrough tumor therapy, ZetaMet™ (Zeta-BC-003) and ZetaMAST™ (Zeta-MBC-005) will be used to train AI-inspired machine learning tool.


Use access

“Patients are at the center of everything that we do. Our goal is to provide breakthrough therapies to all patients that suffer from metastatic cancers, providing relief and hope.” - Joe C. Loy

What IS compassionate Use?

Compassionate Use means making a new, unapproved therapy available to treat a seriously ill patient when other treatments have failed and no others are available.

Therapies that are being tested but have not yet been approved by the FDA are called investigational therapies. These therapies are normally available only to people who are taking part in a clinical trial.
The usual way to get treatment with an unapproved drug is through a clinical trial. But many people with life-threatening diseases can’t find clinical trials that they can be a part of. This could be because they live too far from locations where the studies are being conducted, or because they don’t meet the inclusion criteria.

If you have questions concerning Compassionate Use Access for any of Zetagen’s products, please contact us at